Elevated SNRPA1, as a Promising Predictor Reflecting Severe Clinical Outcome via Effecting Tumor Immunity for ccRCC, Is Related to Cell Invasion, Metastasis, and Sunitinib Sensitivity

Jiang, Aimin; Meng, Jialin; Gong, Wenliang; Zhang, Zhonghua; Gan, Xinxin; Wang, Jie; Wu, Zhenjie; Liu, Bing; Qu, Le; Wang, Linhui

doi:10.3389/fimmu.2022.842069

Cited by 16 publications

(17 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First of all, our research is mainly based on the public database, as a consequence of that, it lacked evidence from the laboratory data. Unlike some recent research studies, the research conducted by the Jiang et al not only explored the function of it based on the database but also successfully demonstrated the function of the SNRPA1 for the ccRCC cells; the research successfully demonstrated that knocking down the SNRPA1 made tumor cells less invasive [ 26 ]. Similarly, the research conducted by Gao et al had also used the same exploring pattern in the pan-cancer analysis of the PRDXs and demonstrated the pathway of the gene in the lab [ 27 ].…”

Section: Discussionmentioning

confidence: 99%

[Retracted] Pan‐Cancer Analysis of Prognostic and Immune Infiltrates for the TMEM65, Especially for the Breast Cancer

Song

Wang

Feng

et al. 2023

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Introduction. Transmembrane protein 65 (TMEM65) is an inner mitochondrial membrane protein, which played important role in mediating autophagy, smooth muscle contraction, protein glycosylation, and immune response. In recent years, the interest had risen for exploring the function of the TMEM genes in the cancer fields. As a consequence, in our pan-cancer research of the TMEM65, we explored the function of the gene in kinds of database and tried to apply the finding in the clinical practice. Methods. In this research, we provide a comprehensive investigation of TMEM65 expression in a pan-cancer manner containing 33 cancer types. We evaluated the association of TMEM65 with the prognosis, immune infiltration, drug sensitivity analysis, GSVA enrichment analysis, TMB, MSI, NEO, and hotspot mechanisms. Results. TMEM65 was abnormally expressed in 24 types of cancers and showed correlation with the OS for 6 cancers and PFI for 9 cancers and kpI for 3 types. Moreover, the TME score, CD8 T effector, and immune checkpoint scoring systems showed a close correlation with the TMEM65. Moreover, TMEM65 was strongly correlated with some of the most common tumor-related genes and certain pathways (TGF beta signaling, TNFA signaling, hypoxia, pyroptosis, DNA repairing, autophagy, ferroptosis, and other related genes). Additionally, the TMEM65 showed correlations with the tumor mutational burden (TMB), microsatellite instability (MSI), NEO, and drug sensitivity. Finally, we confirmed several pathways by the GSEA and GSVA for the TMEM65 at the breast cancer aspects. Nomogram prediction model was also established for the breast tumors based on the TMEM65 level and other variables. Conclusion. Above all, the TMEM65 played important roles in predicting the prognosis of the cancers and correlated with the tumor immunity in the pan-cancer analysis.

show abstract

Section: Discussionmentioning

confidence: 99%

[Retracted] Pan‐Cancer Analysis of Prognostic and Immune Infiltrates for the TMEM65, Especially for the Breast Cancer

Song

Wang

Feng

et al. 2023

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…In more detail, LINC01087 seemed to interfere with 2 miRNAs targeting the messenger of C8orf37 (namely has-miR-644a and has-miR-7-5p), EFNA5 (hsa-miR-1305, hsa-miR-92a-3p), HOOK3 (hsa-miR-4505, hsa-miR-181a-5p), MYOZ3 (hsa-miR-7975, hsa-miR-197-3p), and PCP4L1 (hsa-miR-4505, hsa-miR-423-5p), with 3 miRNAs targeting the mRNAs of SLC2A3 (hsa-miR-606, hsa-miR-34a-5p, hsa-miR-98-5p) and SNRPA1 (hsa-miR-3174, hsa-miR-34a-5p, hsa-miR-98-5p), and 4 miRNAs interfering with the transcripts of IQCG (hsa-miR-3671, hsa-miR-181a-5p, hsa-miR-181b-5p, hsa-miR-181d-5p), PLAG1 (hsa-miR-569, hsa-miR-181a-5p, hsa-miR-181b-5p, hsa-miR-98-5p), and POLI (hsa-miR-4255, hsa-miR-19a-3p, hsa-miR-19b-3p, hsa-miR-92a-3p). Interestingly, most of these mRNAs and miRNAs have been connected to tumor suppressive and/or oncogenic functions in multiple cancers [ 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 ].…”

Section: Resultsmentioning

confidence: 99%

“…The gene SNRPA1 , a spliceosome component responsible for processing pre-mRNA into mRNA, showed strong prognostic potential in prostate cancer, HCC, and ccRCC [ 55 , 117 , 118 ]. Its oncogenic role in CRC has also been demonstrated [ 119 ].…”

Section: Discussionmentioning

confidence: 99%

Systematic Investigation of the Diagnostic and Prognostic Impact of LINC01087 in Human Cancers

Palma

Carbonnier

Salvatore

et al. 2022

Cancers

View full text Add to dashboard Cite

(1) Background: Long non-coding RNAs may constitute epigenetic biomarkers for the diagnosis, prognosis, and therapeutic response of a variety of tumors. In this context, we aimed at assessing the diagnostic and prognostic value of the recently described long intergenic non-coding RNA 01087 (LINC01087) in human cancers. (2) Methods: We studied the expression of LINC01087 across 30 oncological indications by interrogating public resources. Data extracted from the TCGA and GTEx databases were exploited to plot receiver operating characteristic curves (ROC) and determine the diagnostic performance of LINC01087. Survival data from TCGA and KM-Plotter directories allowed us to graph Kaplan–Meier curves and evaluate the prognostic value of LINC01087. To investigate the function of LINC01087, gene ontology (GO) annotation and Kyoto Encyclopedia of Gene and Genomes (KEGG) enrichment analyses were performed. Furthermore, interactions between LINC01087 and both miRNA and mRNA were studied by means of bioinformatics tools. (3) Results: LINC01087 was significantly deregulated in 7 out of 30 cancers, showing a predominant upregulation. Notably, it was overexpressed in breast (BC), esophageal (ESCA), and ovarian (OV) cancers, as well as lung squamous cell carcinoma (LUSC), stomach adenocarcinoma (STAD), and uterine carcinosarcoma (UCS). By contrast, LINC01087 displayed downregulation in testicular germ cell tumors (TGCT). ROC curve analyses identified LINC01087 as a potential diagnostic indicator in BC, ESCA, OV, STAD, and TGCT. Moreover, high and low expression of LINC01087 predicted a favorable prognosis in BC and papillary cell carcinoma, respectively. In silico analyses indicated that deregulation of LINC01087 in cancer was associated with a modulation of genes related to ion channel, transporter, and peptide receptor activity. (4) Conclusions: the quantification of an altered abundance of LINC01087 in tissue specimens might be clinically useful for the diagnosis and prognosis of some hormone-related tumors, including BC, OV, and TGCT, as well as other cancer types such as ESCA and STAD. Moreover, our study revealed the potential of LINC01087 (and perhaps other lncRNAs) to regulate neuroactive molecules in cancer.

show abstract

“…With the rapid development of immunotherapy for ccRCC in recent years, resistance, increasing recurrence rates, and side effects have surfaced, and there are indications that new biomarkers or therapy target for predicting efficacy and prognosis are in urgent need of discovery [47]. Although ccRCC is deemed as immune cell infiltrationhigh tumor, it is also notorious for immune dysfunction and depletion [48][49][50]. It is urgent to comprehensively analyze the mechanism of this abrogated immunity phenomenon in ccRCC.…”

Section: Discussionmentioning

confidence: 99%

CCNA2 as an Immunological Biomarker Encompassing Tumor Microenvironment and Therapeutic Response in Multiple Cancer Types

Jiang

Zhou

Gong

et al. 2022

Oxidative Medicine and Cellular Longevity

Self Cite

View full text Add to dashboard Cite

Background. Cancer is a major threat to human health worldwide. Although recent innovations and advances in early detection and effective therapies such as targeted drugs and immune checkpoint inhibitors have saved more lives of cancer patients and improved their quality of life, our knowledge about cancer remains largely unknown. CCNA2 belongs to the cell cyclin family and has been demonstrated to be a tumorigenic gene in multiple solid tumor types. The aim of the present study was to make a comprehensive analysis on the role of CCNA2 at a pancancer level. Methods. Multidatabases were collected to evaluate the different expression, prognostic value, DNA methylation, tumor mutation burden, microsatellite instability, mismatch repair, tumor immune microenvironment, and drug sensitivity of CCNA2 across pancancer. IHC was utilized to validate the expression and prognostic value of CCNA2 in ccRCC patients from SMMU cohort. Results. CCNA2 was differentially expressed in most cancer types vs. normal tissues. CCNA2 may significantly influence the prognosis of multiple cancer types, especially clear cell renal cell carcinoma (ccRCC). CCNA2 was also frequently mutated in most cancer types. Notably, CCNA2 was significantly correlated with immune cell infiltration and immune checkpoint inhibitory genes. In addition, CCNA2 was also strongly related to drug resistance. Conclusion. CCNA2 may prove to be a new biomarker for prognostic prediction, tumor immunity assessment, and drug susceptibility evaluation in pancancer level, especially in ccRCC.

show abstract

Elevated SNRPA1, as a Promising Predictor Reflecting Severe Clinical Outcome via Effecting Tumor Immunity for ccRCC, Is Related to Cell Invasion, Metastasis, and Sunitinib Sensitivity

Cited by 16 publications

References 43 publications

[Retracted] Pan‐Cancer Analysis of Prognostic and Immune Infiltrates for the TMEM65, Especially for the Breast Cancer

[Retracted] Pan‐Cancer Analysis of Prognostic and Immune Infiltrates for the TMEM65, Especially for the Breast Cancer

Systematic Investigation of the Diagnostic and Prognostic Impact of LINC01087 in Human Cancers

CCNA2 as an Immunological Biomarker Encompassing Tumor Microenvironment and Therapeutic Response in Multiple Cancer Types

Contact Info

Product

Resources

About